


CDPG meeting

27 May 2021





20 CARICOM Countries and CARICOM Associate Countries
 Antigua and Barbuda, Bahamas, Barbados, Belize, Dominica, Grenada, Guyana, Haiti, Jamaica, St Kitts and Nevis, St Lucia, St Vincent and the Grenadines, Suriname, Trinidad and Tobago, Anguilla, British Virgin Islands, Bermuda, Cayman Islands, Montserrat, Turks and Caicos

Cumulative cases
154.744

Cumulative deaths
3011

Cumulative recovered
113.828


29 CARICOM Countries and Associate Countries, and Dutch and French Territories
 Antigua and Barbuda, Bahamas, Barbados, Belize, Dominica, Grenada, Guyana, Haiti, Jamaica, St Kitts and Nevis, St Lucia, St Vincent and the Grenadines, Suriname, Trinidad and Tobago, Anguilla, British Virgin Islands, Bermuda, Cayman Islands, Montserrat, Turks and Caicos, Aruba, Curacao, St Maarten, Bonaire, St Eustatius, Saba, French Guiana, Guadeloupe, Martinique

Cumulative cases
233.395

Cumulative deaths
3747

Cumulative recovered
152.853

Cases % change last 14 days



Decline in cases: 8 countries

Over 100% increase in 4 countries (St. Kitts and Nevis, Dominica, Cayman Islands, Haiti)

Deaths % change last 14 days



Decline in deaths: 5 countries

2-3 Increase: 3 countries (Trinidad and Tobago, Jamaica, Surinam, Barbados)

COVID-19 Vaccine Access and Deployment in the Caribbean

Total doses administered

1,243,785 [1, 7]

Completed schedule

307,421 [2, 7]

1st doses administered

937,261 [3, 6, 7]

2nd doses administered

307,421 [4, 6, 7]

COVAX

1st WAVE

Countries	Quantity Doses	Arrival Date	Supplier	Buyer	Status
13	343,200	Mar/Apr	AstraZeneca AB	PAHO	Arrived


2nd WAVE

Countries	Quantity Doses	Arrival Date	Supplier	Buyer	Status
10	326,400	Apr/May	AstraZeneca AB	PAHO	Arrived

Cumulative Doses administered

Cumulative doses administered

Calendar week



Retos de vacunación/Immunization challenges

- Access to vaccines to cover the 80 % of population not currently covered by COVAX
- Funding for COVID-19 vaccines
- Vaccine hesitancy
- Falling coverage of routine vaccination
- Reduced surveillance of vaccine preventable diseases
 - Measles
 - Rubella
 - Polio



Status of COVID-19 vaccines within WHO EUL/PQ


18 May 2021

	Manufacturer / WHO EUL holder	Name of Vaccine	NRA of Record	Platform	EOI accepted	Pre-submission meeting held	Dossier accepted for review*	Status of assessment**	Anticipated decision date***
1.		BNT162b2/COMIRNATY Tozinameran (INN)	EMA	Nucleoside modified mRNA	✓	✓	✓	Finalized	31/12/20
2.		AZD1222	EMA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	Accepted core data	Finalized	16 April 2021
							Data for Covax sites expected in April 2021 onwards	Finalized: SK-Catalent Wuxi (DS) Other sites	16 April 2021 30 April 2021 As submitted
3.		AZD1222	MFDS KOREA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized	15 Feb 2021
4.		Covishield (ChAdOx1_nCoV-19)	DCGI	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized	15 Feb 2021
5.		Ad26.COV2.5	EMA	Recombinant, replication-incompetent adenovirus type 26 (Ad26) vectored vaccine encoding the (SARS-CoV-2) Spike (S) protein	✓	✓	Core data	Finalized (US +NL sites)	12 March 2021
							Additional sites: - Aspen South Africa - Other sites	- Ongoing - Awaited	- May 2021 - As submitted
6.		mRNA-1273	EMA	mRNA-based vaccine encapsulated in lipid nanoparticle (LNP)	✓	✓	✓	Finalized	30 April 2021
7.		SARS-CoV-2 Vaccine (Vero Cell), Inactivated (InCoV)	NMPA	Inactivated, produced in Vero cells	✓	✓	✓	Finalized	07 May 2021
8.		SARS-CoV-2 Vaccine (Vero Cell), Inactivated	NMPA	Inactivated, produced in Vero cells	✓	✓	✓	In progress	May 2021
9.		Sputnik V	Russian NRA	Human Adenovirus Vector-based Covid-19 vaccine	Additional information submitted	Several meetings held.	"Rolling" submission of clinical and CMC data has started.	Additional data (Non-CLIN, CLIN, CMC) Required. Inspections in April, May and June 2021	Will be set after all data is submitted and inspections completed.
10.		Ad5-nCoV	NMPA	Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)	✓	✓	Rolling data starting May 2021		
11.		NVX-CoV2373/Covovax	EMA	No pre-submission meeting yet.	Submitted EOI on 23 Feb	✓			

Latest Publications and Technical Guidance



[Preventing and mitigating COVID-19 at work](#)



[34th Regulatory update](#)



[COVID-19 Natural immunity](#)

Other updates and key messages



Home / Newsroom / Feature stories / Detail / WHO advises that ivermectin only be used to treat COVID-19 with

WHO advises that ivermectin only be used to treat COVID-19 within clinical trials

- [PAHO. Ongoing Living Update of Potential COVID-19 Therapeutics Options: Summary of Evidence. Rapid Review.](#)
- Ivermectin may not significantly reduce mortality and probably does not improve time to symptom resolution.

- **US administration will provide at least 80 million COVID-19 vaccines for Global use.** The United States will work with COVAX and other partners to ensure these vaccines are delivered in a way that is equitable and follows the science and public health data. The United States will not use its vaccines to secure favors from other countries.



Thank you